The most effective weight loss medications available right now are the newer injectable drugs that mimic gut hormones: tirzepatide (Zepbound) and semaglutide (Wegovy). In a head-to-head trial, tirzepatide produced 20.2% body weight loss compared to 13.7% for semaglutide, making it the clear frontrunner. But these aren’t the only options. Several oral medications also have FDA approval for weight management, and the best choice depends on your medical history, insurance coverage, and how much weight you need to lose.
How the Top Drugs Compare
Weight loss medications fall into two broad categories: the newer injectables that target gut hormones, and older oral pills that work through different mechanisms. Here’s how the major FDA-approved options stack up in terms of raw effectiveness for losing at least 5% of body weight:
- Phentermine/topiramate (Qsymia): The most effective oral option. For every three people who take it, one achieves meaningful weight loss who wouldn’t have on placebo alone. It works by suppressing appetite through two different pathways simultaneously.
- GLP-1 receptor agonists (Wegovy, Zepbound): Similar success rates to phentermine/topiramate for hitting the 5% threshold, but they pull far ahead for larger weight loss. These drugs deliver 14% to 20% total body weight reduction in clinical trials.
- Naltrexone/bupropion (Contrave): An oral pill that targets the brain’s reward and hunger centers. Effective, but has the highest rate of people quitting due to side effects among the major options.
- Orlistat (Xenical, Alli): Blocks fat absorption in the gut. Less effective overall, with about one in five people needing to take it before one achieves clinically meaningful loss beyond what diet alone provides.
Tirzepatide vs. Semaglutide
These two injectables dominate the conversation for good reason. Both are self-administered weekly injections, both require a gradual dose increase over several months, and both produce weight loss that was previously only achievable through surgery. The difference is in their biology.
Semaglutide (Wegovy) activates a single hormone receptor called GLP-1, which slows stomach emptying, reduces appetite, and helps regulate blood sugar. Tirzepatide (Zepbound) activates two receptors: GLP-1 and another called GIP. That second receptor adds effects in the brain’s appetite centers and influences how the body stores and burns fat. In the SURMOUNT-5 trial, which tested both drugs directly against each other, tirzepatide’s dual action translated to roughly 6.5 percentage points more weight loss.
Wegovy recently became available as a daily pill in addition to the weekly injection. The tablet version goes through a monthly dose escalation over about three months before reaching its maintenance dose. The injectable version follows a similar ramp-up over about four months, starting with a small weekly dose and increasing every four weeks.
What These Drugs Feel Like Day to Day
The most common experience on GLP-1 based medications is a dramatic reduction in food noise, that constant background hum of thinking about your next meal. Most people describe feeling satisfied with smaller portions and losing interest in snacking. The flip side is gastrointestinal discomfort, especially in the first few months. Nausea, constipation, and sometimes vomiting are the main reasons people stop taking these drugs.
The gradual dose increases exist specifically to minimize these effects. Your body adjusts to each dose level before moving to the next one. Most GI side effects peak in the first 60 days and then ease off. For the oral options, Contrave commonly causes nausea and headaches, while orlistat is notorious for oily stools and urgent bowel movements when you eat high-fat foods.
Serious Risks to Know About
Pancreatitis is the most talked-about rare complication of GLP-1 drugs. In clinical trials, acute pancreatitis occurred in roughly 0.3% to 0.4% of people taking semaglutide or tirzepatide. That’s low, but it’s slightly higher than in people taking placebo. The risk is more significant if you have a history of pancreatitis: one Cleveland Clinic review found that 10% of patients with prior pancreatitis experienced a recurrence after starting a GLP-1 medication.
For phentermine/topiramate, the concerns are different. Topiramate can cause tingling in the hands and feet, cognitive fog, and carries a risk of birth defects, so it’s not prescribed to anyone who may become pregnant. Phentermine, a stimulant, can raise heart rate and blood pressure.
The Muscle Loss Question
Whenever you lose a significant amount of weight quickly, some of that loss comes from lean tissue, not just fat. On GLP-1 medications, roughly 25% of total weight lost is lean mass (mostly muscle), with the remaining 75% being fat. That ratio is actually similar to what happens with diet-induced weight loss, so these drugs aren’t uniquely muscle-wasting. Still, losing 20% of your body weight means a meaningful absolute amount of muscle disappears along with the fat. Resistance training during treatment is the most reliable way to preserve it.
Weight Regain After Stopping
This is the uncomfortable reality of current weight loss medications: they work while you take them, and most of the benefit reverses when you stop. A meta-analysis published in The Lancet found that one year after stopping a GLP-1 drug, people had regained 60% of the weight they lost during treatment. The regain eventually plateaus at around 75% of the original loss. This means someone who lost 40 pounds on medication would typically regain about 30 of those pounds within a couple of years of stopping. For most people, these drugs are a long-term or indefinite commitment.
Who Qualifies for a Prescription
The general eligibility criteria for prescription weight loss medications are a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. Qualifying conditions include type 2 diabetes, high blood pressure, obstructive sleep apnea, high cholesterol, polycystic ovary syndrome, and fatty liver disease. Some of these medications are also approved for adolescents aged 12 and older who meet specific weight thresholds.
Cost and Access
Price remains the biggest barrier for the injectable options. Wegovy’s list price sits around $1,350 per month, while Zepbound comes in at roughly $1,086 per month. Insurance coverage varies enormously. Some commercial plans cover these drugs fully with a prior authorization, others exclude them entirely, and Medicare has historically not covered weight loss medications, though this is evolving. The older oral medications are all available as generics and cost a fraction of the injectables, which is one reason they remain relevant despite being less effective.
Manufacturer savings programs can reduce costs significantly for people with commercial insurance. If you’re paying entirely out of pocket, the oral options or compounded versions (where legally available) may be more sustainable for long-term use.
What’s Coming Next
The next generation of weight loss drugs targets three hormone receptors simultaneously instead of one or two. Retatrutide, a triple agonist that activates GLP-1, GIP, and glucagon receptors, has shown greater weight loss than current dual agonists in early trials. The glucagon component adds something the current drugs lack: it directly increases the body’s energy expenditure and fat burning, rather than relying solely on appetite reduction. These triple agonists are still in late-stage clinical trials and not yet FDA-approved, but they represent where the field is heading.